A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Rigshospitalet, Copenhagen

Monash Medical Centre, Clayton

The Queen Elizabeth Hospital, Woodville South

National Taiwan University Hospital, Taipei

New York University Grossman School of Medicine and New York University Langone Hospitals, New York

Columbia University Irving Medical Center, New York

Memorial Sloan Kettering Cancer Center, New York

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do

Duke University, Durham

Hospital Universitario Ramon y Cajal, Madrid

Prisma Health Upstate, Greenville

Community Health Network MD Anderson Cancer Center - North, Indianapolis

University of Michigan, Ann Arbor

Health Partners Cancer Center at Regions Hospital, Saint Paul

National Cheng Kung University Hospital, Tainan City

Next Oncology, Irving

University of Texas MD Anderson Cancer Center, Houston

Sarah Cannon Research Institute, Denver

City of Hope National Medical Center, Duarte

Dana Farber Cancer Institute, Boston

Astera Cancer Care, East Brunswick

Cross Cancer Institute, Edmonton

Princess Margaret Cancer Centre, Toronto

Seoul National University Hospital, Seoul

Severance Hospital Yonsei University Health System, Seoul

Asan Medical Center, Seoul

Hospital Universitari Vall d Hebron, Barcelona